Targeted nuclear medicine. Seek and destroy
VM Tolmachev, VI Chernov… - Russian Chemical …, 2022 - iopscience.iop.org
The targeted delivery of radionuclides to tumours holds great promise for diagnosis and
treatment of malignant neoplasms. The development of scaffold proteins has significantly …
treatment of malignant neoplasms. The development of scaffold proteins has significantly …
Imaging using radiolabelled targeted proteins: Radioimmunodetection and beyond
The use of radiolabelled antibodies was proposed in 1970s for staging of malignant
tumours. Intensive research established chemistry for radiolabelling of proteins and …
tumours. Intensive research established chemistry for radiolabelling of proteins and …
Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3
A Vorobyeva, A Schulga, E Konovalova, R Güler… - Scientific Reports, 2019 - nature.com
Radionuclide molecular imaging of HER2 expression in disseminated cancer enables
stratification of patients for HER2-targeted therapies. DARPin G3, a small (14 kDa) …
stratification of patients for HER2-targeted therapies. DARPin G3, a small (14 kDa) …
PET and SPECT imaging of the EGFR family (RTK class I) in oncology
The human epidermal growth factor receptor family (EGFR-family, other designations: HER
family, RTK Class I) is strongly linked to oncogenic transformation. Its members are …
family, RTK Class I) is strongly linked to oncogenic transformation. Its members are …
124I-Labeled Monoclonal Antibody and Fragment for the Noninvasive Evaluation of Tumor PD-L1 Expression In Vivo
Y Cheng, D Shi, Z Xu, Z Gao, Z Si, Y Zhao… - Molecular …, 2022 - ACS Publications
Lung cancer is a highly heterogeneous cancer and is divided broadly into small and
nonsmall cell lung cancer (SCLC or NSCLC). In all NSCLC patients, it is estimated that 50 …
nonsmall cell lung cancer (SCLC or NSCLC). In all NSCLC patients, it is estimated that 50 …
Synthesis, 123I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their …
LA Hasnowo, MS Larkina, E Plotnikov… - International Journal of …, 2023 - mdpi.com
Prostate-specific membrane antigen (PSMA) has been identified as a target for the
development of theranostic agents. In our current work, we describe the design and …
development of theranostic agents. In our current work, we describe the design and …
Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer
M Larkina, E Plotnikov, E Bezverkhniaia… - International Journal of …, 2022 - mdpi.com
Non-invasive radionuclide imaging of human epidermal growth factor receptor type 2
(HER2) expression in breast, gastroesophageal, and ovarian cancers may stratify patients …
(HER2) expression in breast, gastroesophageal, and ovarian cancers may stratify patients …
The production of the first functional antibody mimetic in higher plants: the chloroplast makes the DARPin G3 for HER2 imaging in oncology
M Ehsasatvatan, BB Kohnehrouz, A Gholizadeh… - Biological Research, 2022 - Springer
Background Designed mimetic molecules are attractive tools in biopharmaceuticals and
synthetic biology. They require mass and functional production for the assessment of …
synthetic biology. They require mass and functional production for the assessment of …
[HTML][HTML] Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1
SM Deyev, A Vorobyeva, A Schulga… - International journal of …, 2020 - Elsevier
Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying
patients for specific biotherapeutics. New type of imaging probes, based on designed …
patients for specific biotherapeutics. New type of imaging probes, based on designed …
On the prevention of kidney uptake of radiolabeled DARPins
Background Designed ankyrin repeat proteins (DARPins) are small engineered scaffold
proteins (14–18 kDa) that demonstrated promising tumor-targeting properties in preclinical …
proteins (14–18 kDa) that demonstrated promising tumor-targeting properties in preclinical …